Shah Nimish P 4
4 · Instil Bio, Inc. · Filed Mar 25, 2021
Insider Transaction Report
Form 4
Shah Nimish P
Director
Transactions
- Conversion
Common Stock
2021-03-23+430,431→ 5,531,297 total(indirect: See footnote) - Conversion
Common Stock
2021-03-23+480,716→ 480,716 total(indirect: See footnote) - Purchase
Common Stock
2021-03-23$20.00/sh+19,620$392,400→ 19,620 total(indirect: See footnote) - Conversion
Series C Preferred Stock
2021-03-23−400,597→ 0 total(indirect: See footnote)→ Common Stock (480,716 underlying) - Conversion
Common Stock
2021-03-23+5,100,866→ 5,100,866 total(indirect: See footnote) - Conversion
Common Stock
2021-03-23+43,033→ 553,063 total(indirect: See footnote) - Purchase
Common Stock
2021-03-23$20.00/sh+10,470$209,400→ 563,533 total(indirect: See footnote) - Purchase
Common Stock
2021-03-23$20.00/sh+104,640$2,092,800→ 5,635,937 total(indirect: See footnote) - Purchase
Common Stock
2021-03-23$20.00/sh+116,880$2,337,600→ 597,596 total(indirect: See footnote) - Conversion
Series B Preferred Stock
2021-03-23−4,250,722→ 0 total(indirect: See footnote)→ Common Stock (5,100,866 underlying) - Conversion
Series C Preferred Stock
2021-03-23−358,693→ 0 total(indirect: See footnote)→ Common Stock (430,431 underlying) - Purchase
Common Stock
2021-03-23$20.00/sh+48,390$967,800→ 48,390 total(indirect: See footnote) - Conversion
Series B Preferred Stock
2021-03-23−425,025→ 0 total(indirect: See footnote)→ Common Stock (510,030 underlying) - Conversion
Series C Preferred Stock
2021-03-23−35,861→ 0 total(indirect: See footnote)→ Common Stock (43,033 underlying) - Conversion
Common Stock
2021-03-23+510,030→ 510,030 total(indirect: See footnote)
Footnotes (6)
- [F1]Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1.2 for one basis, and had no expiration date.
- [F2]The securities are held by Venrock Healthcare Capital Partners III, L.P. ("Partners III"). VHCP Management III, LLC ("Management III") is the sole general partner of Partners III. The Reporting Person is a voting member of Management III and may be deemed to share voting and investment power with respect to the shares held by Partners III and disclaims Section 16 beneficial ownership of such securities held by Partners III, except to the extent of his pecuniary interest therein, if any.
- [F3]The shares are held by VHCP Co-Investment Holdings III, LLC ("Holdings III"). Management III is the manager of Holdings III. The Reporting Person is a voting member of Management III and may be deemed to share voting and investment power with respect to the shares held by Holdings III and disclaims Section 16 beneficial ownership of such securities held by Holdings III, except to the extent of his pecuniary interest therein, if any.
- [F4]The securities are held by Venrock Healthcare Capital Partners EG, L.P. ("Partners EG"). VHCP Management EG, LLC ("Management EG") is the sole general partner of Partners EG. The Reporting Person is a voting member of Management EG and may be deemed to share voting and investment power with respect to the shares held by Partners EG and disclaims Section 16 beneficial ownership of such securities held by Partners EG, except to the extent of his pecuniary interest therein, if any.
- [F5]The securities are held by Venrock Healthcare Capital Partners II, L.P. ("Partners II"). VHCP Management II, LLC ("Management II") is the sole general partner of Partners II. The Reporting Person is a voting member of Management II and may be deemed to share voting and investment power with respect to the shares held by Partners II and disclaims Section 16 beneficial ownership of such securities held by Partners II, except to the extent of his pecuniary interest therein, if any.
- [F6]The shares are held by VHCP Co-Investment Holdings II, LLC ("Holdings II"). Management II is the manager of Holdings II. The Reporting Person is a voting member of Management II and may be deemed to share voting and investment power with respect to the shares held by Holdings II and disclaims Section 16 beneficial ownership of such securities held by Holdings II, except to the extent of his pecuniary interest therein, if any.